RARE Valuation
Ultragenyx Pharmaceutical Inc
$
30.860
- Overview
- Forecast
- Valuation
- Earnings
RARE Relative Valuation
RARE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RARE is overvalued; if below, it's undervalued.
Historical Valuation
Ultragenyx Pharmaceutical Inc (RARE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.97. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：31.09
Fair
-6.27
PE
1Y
3Y
5Y
Trailing
Forward
-8.20
EV/EBITDA
Ultragenyx Pharmaceutical Inc. (RARE) has a current EV/EBITDA of -8.20. The 5-year average EV/EBITDA is -10.47. The thresholds are as follows: Strongly Undervalued below -23.84, Undervalued between -23.84 and -17.15, Fairly Valued between -3.79 and -17.15, Overvalued between -3.79 and 2.89, and Strongly Overvalued above 2.89. The current Forward EV/EBITDA of -8.20 falls within the Historic Trend Line -Fairly Valued range.
-6.98
EV/EBIT
Ultragenyx Pharmaceutical Inc. (RARE) has a current EV/EBIT of -6.98. The 5-year average EV/EBIT is -10.07. The thresholds are as follows: Strongly Undervalued below -22.04, Undervalued between -22.04 and -16.06, Fairly Valued between -4.09 and -16.06, Overvalued between -4.09 and 1.90, and Strongly Overvalued above 1.90. The current Forward EV/EBIT of -6.98 falls within the Historic Trend Line -Fairly Valued range.
4.05
PS
Ultragenyx Pharmaceutical Inc. (RARE) has a current PS of 4.05. The 5-year average PS is 10.77. The thresholds are as follows: Strongly Undervalued below -2.64, Undervalued between -2.64 and 4.06, Fairly Valued between 17.47 and 4.06, Overvalued between 17.47 and 24.17, and Strongly Overvalued above 24.17. The current Forward PS of 4.05 falls within the Undervalued range.
-9.02
P/OCF
Ultragenyx Pharmaceutical Inc. (RARE) has a current P/OCF of -9.02. The 5-year average P/OCF is -4.44. The thresholds are as follows: Strongly Undervalued below -86.63, Undervalued between -86.63 and -45.54, Fairly Valued between 36.65 and -45.54, Overvalued between 36.65 and 77.74, and Strongly Overvalued above 77.74. The current Forward P/OCF of -9.02 falls within the Historic Trend Line -Fairly Valued range.
92.44
P/FCF
Ultragenyx Pharmaceutical Inc. (RARE) has a current P/FCF of 92.44. The 5-year average P/FCF is -9.39. The thresholds are as follows: Strongly Undervalued below -55.37, Undervalued between -55.37 and -32.38, Fairly Valued between 13.61 and -32.38, Overvalued between 13.61 and 36.60, and Strongly Overvalued above 36.60. The current Forward P/FCF of 92.44 falls within the Strongly Overvalued range.
Ultragenyx Pharmaceutical Inc (RARE) has a current Price-to-Book (P/B) ratio of 18.91. Compared to its 3-year average P/B ratio of 21.42 , the current P/B ratio is approximately -11.72% higher. Relative to its 5-year average P/B ratio of 15.45, the current P/B ratio is about 22.38% higher. Ultragenyx Pharmaceutical Inc (RARE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -14.45%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -11.28% , the current FCF yield is about -100.00% lower.
18.91
P/B
Median3y
21.42
Median5y
15.45
-14.71
FCF Yield
Median3y
-14.45
Median5y
-11.28
Competitors Valuation Multiple
The average P/S ratio for RARE's competitors is 0.00, providing a benchmark for relative valuation. Ultragenyx Pharmaceutical Inc Corp (RARE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 13.24%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RARE decreased by 41.67% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 147.03M to 166.50M.
The secondary factor is the Margin Expansion, contributed -22.87%to the performance.
Overall, the performance of RARE in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
NVDA
NVIDIA Corp
189.110
USD
+2.20%
META
Meta Platforms Inc
717.840
USD
+0.67%
MSFT
Microsoft Corp
524.850
USD
+0.17%
AMZN
Amazon.com Inc
225.220
USD
+1.55%
TSLA
Tesla Inc
438.690
USD
+1.29%
GOOGL
Alphabet Inc
244.620
USD
-0.46%
AAPL
Apple Inc
258.060
USD
+0.62%
AVGO
Broadcom Inc
345.500
USD
+2.70%
GOOG
Alphabet Inc
245.460
USD
-0.68%
WMT
Walmart Inc
102.900
USD
-0.33%
FAQ
Is Ultragenyx Pharmaceutical Inc (RARE) currently overvalued or undervalued?
Ultragenyx Pharmaceutical Inc (RARE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.97. The fair price of Ultragenyx Pharmaceutical Inc (RARE) is between NaN to NaN according to relative valuation methord.
What is Ultragenyx Pharmaceutical Inc (RARE) fair value?
How does RARE's valuation metrics compare to the industry average?
What is the current P/B ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Oct 08 2025?
What is the current FCF Yield for Ultragenyx Pharmaceutical Inc (RARE) as of Oct 08 2025?
What is the current Forward P/E ratio for Ultragenyx Pharmaceutical Inc (RARE) as of Oct 08 2025?